source
- Moderna delays norovirus vaccine readout, cites insufficient infectionsModerna announced that its norovirus vaccine trial will not yield efficacy data this season because infection rates were lower than expected. The company said it will open an additional trial coho…
- Moderna maintains 10% growth target despite Phase 3 norovirus missModerna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUS…BioSpace · 2h ago↗ source